Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Meningiomas are mainly benign brain tumors, although about 20% of histologically benign cases are clinically aggressive and recur after resection. We hypothesize that meningioma brain invasiveness and recurrence may be related to the presence of cancer stem cells and their high responsiveness to the CXCL12-CXCR4/CXCR7 chemokine axis. The aim of this study was to isolate meningioma stem cells from human samples, characterize them for biological features related to malignant behavior, and to identify the role of CXCR4/CXCR7 in these processes.
METHODS: Meningioma stem cells were isolated from patient-derived primary cultures in stem cell-permissive conditions, and characterized for phenotype, self-renewal, proliferation and migration rates, vasculogenic mimicry (VM), and in vivo tumorigenesis, in comparison with differentiated meningioma cells and stem-like cells isolated from normal meninges. These cell populations were challenged with CXCL12 and CXCL11 and receptor antagonists to define the chemokine role in stem cell-related functions.
RESULTS: Stem-like cells isolated from meningioma cultures display higher proliferation and migration rates, and VM, as compared to meningioma non-stem cells or cells isolated from normal meninges and were the only tumorigenic population in vivo. In meningioma cells, these stem-like functions were under the control of the CXCR4/CXCR7 chemokine axis.
CONCLUSIONS: We report a role for CXCL11 and CXCL12 in the control of malignant features in stem-like cells isolated from human meningioma, providing a possible basis for the aggressive clinical behavior observed in subsets of these tumors. CXCR4/CXCR7 antagonists might represent a useful approach for meningioma at high risk of recurrence and malignant progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Neuro-oncology - 25(2023), 10 vom: 03. Okt., Seite 1775-1787 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barbieri, Federica [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.10.2023 Date Revised 20.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/neuonc/noad076 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355787741 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355787741 | ||
| 003 | DE-627 | ||
| 005 | 20240420232126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/noad076 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM355787741 | ||
| 035 | |a (NLM)37074930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barbieri, Federica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2023 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Meningiomas are mainly benign brain tumors, although about 20% of histologically benign cases are clinically aggressive and recur after resection. We hypothesize that meningioma brain invasiveness and recurrence may be related to the presence of cancer stem cells and their high responsiveness to the CXCL12-CXCR4/CXCR7 chemokine axis. The aim of this study was to isolate meningioma stem cells from human samples, characterize them for biological features related to malignant behavior, and to identify the role of CXCR4/CXCR7 in these processes | ||
| 520 | |a METHODS: Meningioma stem cells were isolated from patient-derived primary cultures in stem cell-permissive conditions, and characterized for phenotype, self-renewal, proliferation and migration rates, vasculogenic mimicry (VM), and in vivo tumorigenesis, in comparison with differentiated meningioma cells and stem-like cells isolated from normal meninges. These cell populations were challenged with CXCL12 and CXCL11 and receptor antagonists to define the chemokine role in stem cell-related functions | ||
| 520 | |a RESULTS: Stem-like cells isolated from meningioma cultures display higher proliferation and migration rates, and VM, as compared to meningioma non-stem cells or cells isolated from normal meninges and were the only tumorigenic population in vivo. In meningioma cells, these stem-like functions were under the control of the CXCR4/CXCR7 chemokine axis | ||
| 520 | |a CONCLUSIONS: We report a role for CXCL11 and CXCL12 in the control of malignant features in stem-like cells isolated from human meningioma, providing a possible basis for the aggressive clinical behavior observed in subsets of these tumors. CXCR4/CXCR7 antagonists might represent a useful approach for meningioma at high risk of recurrence and malignant progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CXCL11/CXCL12 | |
| 650 | 4 | |a meningioma | |
| 650 | 4 | |a stem cells | |
| 650 | 4 | |a tumorigenesis | |
| 650 | 7 | |a Chemokine CXCL12 |2 NLM | |
| 650 | 7 | |a Receptors, CXCR |2 NLM | |
| 650 | 7 | |a Receptors, CXCR4 |2 NLM | |
| 650 | 7 | |a CXCL11 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CXCL11 |2 NLM | |
| 650 | 7 | |a CXCL12 protein, human |2 NLM | |
| 700 | 1 | |a Bajetto, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Dellacasagrande, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Solari, Agnese |e verfasserin |4 aut | |
| 700 | 1 | |a Würth, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Rancati, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Ceresa, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Appolloni, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Giuseppa |e verfasserin |4 aut | |
| 700 | 1 | |a Dono, Mariella |e verfasserin |4 aut | |
| 700 | 1 | |a Nozza, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Schiapparelli, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Gambaro, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Fiaschi, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Gaggero, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Thellung, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Malatesta, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Zona, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a De Pietri Tonelli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Florio, Tullio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-oncology |d 1999 |g 25(2023), 10 vom: 03. Okt., Seite 1775-1787 |w (DE-627)NLM111754321 |x 1523-5866 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:03 |g month:10 |g pages:1775-1787 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/neuonc/noad076 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 03 |c 10 |h 1775-1787 | ||